Project description
AI-based modelling assessing cardiovascular disease patients' response to therapy
Cardiovascular disease (CVD) remains one of the main causes of morbidity and mortality, despite significant advances in therapy, representing an enormous societal burden. Unhealthy lifestyles and population ageing contribute to the growing prevalence. The EU-funded iCARE4CVD project uses AI-based modelling to assess changes in risk and categorise patients based on their responses to therapy, while also considering patient-relevant factors. Results will be validated in new and ongoing large cohorts and a pilot trial to test the prediction of treatment response using multiple biomarkers, in contrast to the current one-size-fits-all approach in CVD treatment. The project aims to provide decision-making tools for individualised therapy based on newly identified subgroups, with patient involvement throughout.
Objective
The burden of cardiovascular disease (CVD) on society is huge with >85 million people affected in Europe. The overall prevalence continues to grow due to unhealthy lifestyles and population aging. Heart failure (HF) is the final common pathway of all CVD and has a 5 year mortality rate of 20-50% despite significant advances in therapy.
iCARE4CVD aims to address this burden by contributing to three essential steps to improve the current care pathways, covering all stages from early risk to established HF: 1) early diagnosis to identify patients at risk of CVD and divide them into clinically meaningful subgroups; 2) risk stratification for these subgroups to define the urgency for intervention; and 3) prediction of treatment response for each subgroup. This will be achieved by the following steps: clinical partners will provide a large set of cohorts including >1,000,000 patients with a wide range of biomarkers (e.g. digital, blood, imaging). Anonymous access to data will be enabled by using a blockchain-supported federated database. Artificial intelligence-based modeling also considering patient relevant factors will assess changes in risk and stratify patients according to their individual responses to therapy. Results will then be prospectively validated in new and ongoing large cohorts and a pilot trial to test the prediction of treatment response by using multiple biomarkers going beyond current risk prediction (such as SCORE) towards individualized therapy. Results will be used to provide novel decision tools for each step targeting newly identified subgroups and as a blueprint for innovative future trials to individualise prevention and therapy. Patient involvement is key in every part of iCARE4CVD (e.g. patient advisory board) to build a motivational framework for self-care by patients. The project brings together an EU-wide consortium with the needed resources and expertise from the public and private side to bring iCARE4CVD to success.
Fields of science
Keywords
Programme(s)
- HORIZON.2.1 - Health Main Programme
- HORIZON.2.1.7 - Innovative Health Initiative
Funding Scheme
HORIZON-JU-RIA - HORIZON JU Research and Innovation ActionsCoordinator
6200 MD Maastricht
Netherlands
See on map
Participants (30)
52074 Aachen
See on map
90762 Furth
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
2440 Geel
See on map
20156 Milano
See on map
1090 Wien
See on map
5656 AE Eindhoven
See on map
9713 GZ Groningen
See on map
20157 Milano
See on map
10117 Berlin
See on map
04109 Leipzig
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
4 Dublin
See on map
2595 DA Den Haag
See on map
3015 GD Rotterdam
See on map
1114 AB Amsterdam-Duivendrecht
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
2333 ZA Leiden
See on map
75654 Paris
See on map
75009 Paris
See on map
2880 Bagsvaerd
See on map
8005 ZURICH
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
22419 Hamburg
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
92100 Boulogne-Billancourt
See on map
10004 New York
See on map
46285 INDIANAPOLIS
See on map
4070 Basel
See on map
151 85 Sodertaelje
See on map
1831 Diegem
See on map
51373 Leverkusen
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
07981 WHIPPANY NEW JERSEY
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
59120 LOOS
See on map
5684 PC Best
See on map
Partners (6)
1214 Vernier
See on map
61352 Bad Homburg
See on map
G12 8QQ Glasgow
See on map
BT7 1NN Belfast
See on map
IP14 5BT Stowmarket
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
1206 Geneve
See on map